Welcome to our dedicated page for Trevena news (Ticker: TRVN), a resource for investors and traders seeking the latest updates and insights on Trevena stock.
Trevena, Inc. (TRVN) is a biopharmaceutical company focused on medicines for central nervous system (CNS) disorders, and its news flow reflects both clinical and corporate developments. Company press releases highlight progress with its approved product OLINVYK (oliceridine) injection for acute pain in adults and its pipeline of investigational CNS candidates, including TRV045, TRV250 and TRV734.
News updates frequently cover clinical and preclinical data for TRV045, a highly selective S1P1 receptor modulator in development for neuropathic pain secondary to diabetic peripheral neuropathy and under exploration for epilepsy through collaborations such as the NIH-supported Epilepsy Therapy Screening Program. Trevena reports results from proof-of-concept studies, preclinical pain and epilepsy models, and ongoing formulation and toxicology work that inform the potential path toward later-stage development.
Investors can also follow commercial and strategic updates related to OLINVYK, including reductions in commercial support, strategic reviews of alternatives for the product, and discussions of how OLINVYK remains available for purchase while the company evaluates options such as sale, license, divestiture or discontinuation of U.S. commercial sales.
Trevena’s news includes capital markets and corporate actions, such as private placements, warrant exercises, royalty-based financing amendments, and a 1-for-25 reverse stock split. The company has reported decisions by the Nasdaq Hearings Panel to delist its common stock, the suspension of trading on Nasdaq, and the commencement of trading on the OTC Pink Open Market and subsequent identification of the OTC Expert Market as the trading venue in SEC filings.
For readers tracking TRVN, the news stream provides context on clinical progress, regulatory and safety information for OLINVYK, financing arrangements, cost-cutting measures, board and management changes, and the company’s ongoing strategic review of its assets.
Trevena, Inc. (Nasdaq: TRVN) has received FDA approval for OLINVYK, addressing acute pain in adults requiring IV opioid analgesics. OLINVYK, a novel chemical entity, is set to launch in Q4 2020 pending controlled substance scheduling by the DEA. The drug's efficacy was established through extensive trials involving over 1,500 patients, demonstrating significant pain relief compared to placebo. With $54.8 million in cash reserves, Trevena is positioned for OLINVYK’s commercialization through 2021.
Trevena, Inc. (Nasdaq: TRVN) announced that its partner in China has received approval from the National Medical Products Administration to begin clinical trials for IV oliceridine, a pain management drug. This regulatory milestone supports Trevena's anticipated PDUFA date on August 7 for U.S. approval. The company expects milestone payments and a 10% royalty on net sales of oliceridine in China. Oliceridine is designed for managing moderate-to-severe acute pain and may have fewer side effects due to its selective action.
Trevena, Inc. (Nasdaq: TRVN) announced a collaboration with Imperial College London to evaluate TRV027, a novel AT1 receptor selective agonist, for treating acute lung injury in COVID-19 patients. This randomized, double-blind study will involve approximately 60 hospitalized patients aged 65 and older to assess TRV027's effect on health outcomes associated with ARDS. TRV027 has shown efficacy and safety in previous trials involving around 700 individuals. The study is supported by the British Heart Foundation Centre for Research Excellence Award.
Summary not available.